title: Ivabradine: Role in the Chronic Heart Failure Armamentarium.
abstract: Ivabradine is approved to reduce hospitalizations for patients with symptomatic heart failure, reduced ejection fraction, and persistently elevated heart rate despite otherwise maximal medical therapy. However, the eligible patient population is a small fraction of those with heart failure overall. This review summarizes the major clinical evidence supporting the use of ivabradine, identifies and discusses areas of uncertainty from the clinical trial data, helps describe the population most likely to benefit, and attempts to place ivabradine within the multifaceted treatment scheme currently used for patients with heart failure and reduced ejection fraction.
authors.affiliation: From School of Medicine, University of California San Francisco (M.A.P., J.R.T.); and Section of Cardiology, San Francisco Veterans Affairs Medical Center, CA (J.R.T.).
authors.forename: Mitchell A
authors.initials: MA
authors.lastname: Psotka
authors.affiliation: From School of Medicine, University of California San Francisco (M.A.P., J.R.T.); and Section of Cardiology, San Francisco Veterans Affairs Medical Center, CA (J.R.T.). john.teerlink@ucsf.edu.
authors.forename: John R
authors.initials: JR
authors.lastname: Teerlink
mesh_terms: D001552:Benzazepines / Q000627:therapeutic use*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic / Q000379:methods; D006333:Heart Failure / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D006760:Hospitalization / Q000639:trends; D006801:Humans; D000077550:Ivabradine
chemical_list: D001552:Benzazepines; D002317:Cardiovascular Agents; D000077550:Ivabradine
keywords: clinical studies as topic; drug therapy; heart failure